Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
AMLODIPINE MALEATE
Norton Waterford
5 Milligram
Tablets
2005-03-24
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Myostin 5 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Amlodipine 5 mg tablets (as maleate): Each tablet contains 5 mg amlodipine equivalent to 6.42 mg amlodipine maleate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. White, round, slightly biconvex, bevel-edged, scored on one side, diameter 8 mm. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS 1. Essential hypertension. 2. Chronic stable and vasospastic angina pectoris. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _In adults_ For treatment of both hypertension and angina pectoris the usual initial dose is 5 mg once daily. If the desired therapeutic effect cannot be achieved within 2-4 weeks this dose may be increased to a maximum dose of 10 mg daily (as single dose) depending on the individual patient’s response. Amlodipine may be used either as monotherapy or in combination with other antianginal drugs in patients with angina. _Children with hypertension from 6 years to 17 years of age_ The recommended antihypertensive oral dose in pediatric patients ages 6-17 years is 2.5 mg once daily as a starting dose, up-titrated to 5 mg once daily if blood pressure goal is not achieved after 4 weeks. Doses in excess of 5 mg daily have not been studied in pediatric patients (see section 5.1 Pharmacodynamic Properties and section 5.2 Pharmacokinetic Properties). The effect of amlodipine on blood pressure in patients less than 6 years of age is not known. The 2.5 mg dose can be obtained with Amlodipine 5 mg tablets as these tablets are manufactured to break into equal halves. _In patients with renal impairment_ In these patients amlodipine can be used in the normal dosage Lesen Sie das vollständige Dokument